Cited by 636Antiplatelet Therapy and Cardiovascular DiseasesPeripheral Artery Disease ManagementCoronary Interventions and Diagnostics

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease

Open access

Hiatt, William R., Fowkes, F. Gerry R., Heizer, Gretchen, Berger, Jeffrey S., Baumgartner, Iris, Held, Peter, Katona, Brian G., Mahaffey, Kenneth W., Norgren, Lars, Jones, W. Schuyler, Blomster, Juuso, Millegård, Marcus, Reist, Craig, Patel, Manesh R.·2017·New England Journal of Medicine

DOI 10.1056/nejmoa1611688

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events. Data from previous trials have suggested that patients receiving clopidogrel monotherapy had a lower risk of cardiovascular events than those receiving aspirin. We wanted to compare clopidogrel with ticagrelor, a potent antiplatelet agent, in patients with peripheral artery disease. METHODS: In this double-blind, event-driven trial, we randomly assigned 13,885 patients with symptomatic peripheral artery disease to receive monotherapy with ticagrelor (90 mg twice daily) or clopidogrel (75 mg once daily). Patients were eligible if they had an ankle-brachial index (ABI) of 0.80 or less or had undergone previous revascularization of the lower limbs. The primary efficacy end point was a composite of adjudicated cardiovascular death, myocardial infarction, or ischemic stroke. The primary safety end point was major bleeding. The median follow-up was 30 months. RESULTS: The median age of the patients was 66 years, and 72% were men; 43% were enrolled on the basis of the ABI and 57% on the basis of previous revascularization. The mean baseline ABI in all patients was 0.71, 76.6% of the patients had claudication, and 4.6% had critical limb ischemia. The primary efficacy end point occurred in 751 of 6930 patients (10.8%) receiving ticagrelor and in 740 of 6955 (10.6%) receiving clopidogrel (hazard ratio, 1.02; 95% confidence interval [CI], 0.92 to 1.13; P=0.65). In each group, acute limb ischemia occurred in 1.7% of the patients (hazard ratio, 1.03; 95% CI, 0.79 to 1.33; P=0.85) and major bleeding in 1.6% (hazard ratio, 1.10; 95% CI, 0.84 to 1.43; P=0.49). CONCLUSIONS: In patients with symptomatic peripheral artery disease, ticagrelor was not shown to be superior to clopidogrel for the reduction of cardiovascular events. Major bleeding occurred at similar rates among the patients in the two trial groups. (Funded by AstraZeneca; EUCLID ClinicalTrials.gov number, NCT01732822 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1611688

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citation
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,819
Long-term use of ticagrelor in patients with prior myocardial infarction
Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., Magnani, G., Bansilal, S., Fish, M. P., Im, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500857 · Cited by 1,999
Self-citation
International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis
Bhatt, D. L. (2006) · JAMA · doi:10.1001/jama.295.2.180 · Cited by 1,644
One-year cardiovascular event rates in outpatients with atherothrombosis
Steg, P. G., Bhatt, D. L., Wilson, P. W. F., D’Agostino, R., Ohman, E. M., Röther, J., Liau, C.-S., Hirsch, A. T., Mas, J.-L., Ikeda, Y., et al. (2007) · JAMA · doi:10.1001/jama.297.11.1197 · Cited by 1,382
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease
Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., Lee, R., Bancroft, J., MacEwan, S., Shepherd, J., et al. (2008) · BMJ · doi:10.1136/bmj.a1840 · Cited by 977
Vorapaxar in the Secondary Prevention of Atherothrombotic Events
Morrow, D. A., Braunwald, E., Bonaca, M. P., Ameriso, S. F., Dalby, A. J., Fish, P., Fox, K. A. A., Lipka, L., Liu, X., Nicolau, J. C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200933 · Cited by 966
Aspirin for Prevention of Cardiovascular Events in a General Population Screened for a Low Ankle Brachial Index<subtitle>A Randomized Controlled Trial</subtitle>
Fowkes, F. G. R. (2010) · JAMA · doi:10.1001/jama.2010.221 · Cited by 624
Self-citation
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease
Bonaca, M. P., Bhatt, D. L., Storey, R. F., Steg, P. G., Cohen, M. C., Kuder, J., Goodrich, E. L., Nicolau, J. C., Parkhomenko, A. N., Lopez-Sendon, J. L., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.524 · Cited by 385
Self-citation

Flagged first, then by citations

Show all 14 references

Sorted by citations

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz425 · Cited by 7,166
2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS)
Aboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx095 · Cited by 3,293
Rivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438
Global Vascular Guidelines on the management of chronic limb-threatening ischemia.
Conte, M. S., Bradbury, A. W., Kolh, P., White, J. V., Dick, F., Fitridge, R., Mills, J. L., Ricco, J.-B., Suresh, K. R., Murad, M. H., et al. (2019) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2019.02.016 · Cited by 2,015
Self-citation
Global vascular guidelines on the management of chronic limb-threatening ischemia
Conte, M. S., Bradbury, A. W., Kolh, P., White, J. V., Dick, F., Fitridge, R., Mills, J. L., Ricco, J.-B., Suresh, K. R., Murad, M. H., et al. (2019) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2019.05.006 · Cited by 1,582
Self-citation
Rivaroxaban in Peripheral Artery Disease after Revascularization
Bonaca, M. P., Bauersachs, R. M., Anand, S. S., Debus, E. S., Nehler, M. R., Patel, M. R., Fanelli, F., Capell, W. H., Diao, L., Jaeger, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2000052 · Cited by 1,045
Self-citation
2024 ESC Guidelines for the management of peripheral arterial and aortic diseases
Mazzolai, L., Teixidó‐Turà, G., Lanzi, S., Boc, V., Bossone, E., Brodmann, M., Bura-Rivière, A., Backer, J. F. A. D., Déglise, S., Corte, A. D., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae179 · Cited by 1,313
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
Anand, S. S., Bosch, J., Eikelboom, J. W., Connolly, S. J., Diaz, R., Widimsky, P., Aboyans, V., Alings, M., Kakkar, A. K., Keltai, K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32409-1 · Cited by 879
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
Vranckx, P., Valgimigli, M., Jüni, P., Hamm, C. W., Steg, P. G., Heg, D., van Es, G. A., McFadden, E. P., Onuma, Y., van Meijeren, C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31858-0 · Cited by 823
2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Gornik, H. L., Aronow, H. D., Goodney, P. P., Arya, S., Brewster, L. P., Byrd, L., Chandra, V., Drachman, D. E., Eaves, J. M., Ehrman, J. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001251 · Cited by 771
Self-citation
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
Bonaca, M. P., Nault, P., Giugliano, R. P., Keech, A. C., Pineda, A. L., Kanevsky, E., Kuder, J., Murphy, S. A., Jukema, J. W., Lewis, B. S., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032235 · Cited by 766
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
Connolly, S. J., Eikelboom, J. W., Bosch, J., Dagenais, G., Dyal, L., Lanas, F., Metsarinne, K., O'Donnell, M., Dans, A. L., Ha, J.-W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32458-3 · Cited by 754
The 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in Collaboration With the European Society for Vascular Surgery (ESVS)
Halliday, A. W., & Bax, J. J. (2018) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2018.03.004 · Cited by 660
Update on peripheral artery disease: Epidemiology and evidence-based facts
Shu, J., & Santulli, G. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.05.033 · Cited by 487
Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease
Anand, S. S., Caron, F., Eikelboom, J. W., Bosch, J., Dyal, L., Aboyans, V., Abola, M. T., Branch, K. R. H., Keltai, K., Bhatt, D. L., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.008 · Cited by 466
Editor's Choice – 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)
Aboyans, V., Ricco, J., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T. U., Collet, J., Czerny, M., Carlo, M. D., Debus, S., et al. (2017) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2017.07.018 · Cited by 1,027
2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease
Gornik, H. L., Aronow, H. D., Goodney, P. P., Arya, S., Brewster, L. P., Byrd, L., Chandra, V., Drachman, D. E., Eaves, J. M., Ehrman, J. K., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.013 · Cited by 294
Self-citation
Diabetes and peripheral artery disease: A review
Soyoye, D. O., Abiodun, O. O., Ikem, R. T., Kolawole, B. A., & Akintomide, A. O. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i6.827 · Cited by 337
Update on the pathophysiology and medical treatment of peripheral artery disease
Golledge, J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00663-9 · Cited by 249
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis
Patrono, C., Morais, J., Baigent, C., Collet, J., Fitzgerald, D. J., Halvorsen, S., Rocca, B., Siegbahn, A., Storey, R. F., & Vilahur, G. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.037 · Cited by 233
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention
Capodanno, D., Mehran, R., Valgimigli, M., Baber, U., Windecker, S., Vranckx, P., Dangas, G., Rollini, F., Kimura, T., Collet, J., et al. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0049-1 · Cited by 220
Evidence-Based Medical Management of Peripheral Artery Disease
Bevan, G. H., & Solaru, K. W. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312142 · Cited by 241
Lower Extremity Peripheral Artery Disease Without Chronic Limb-Threatening Ischemia
Polonsky, T. S., & McDermott, M. M. (2021) · JAMA · doi:10.1001/jama.2021.2126 · Cited by 211
Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases
Twine, C. P., Kakkos, S. K., Aboyans, V., Baumgärtner, I., Behrendt, C., Bellmunt-Montoya, S., Jilma, B., Nordanstig, J., Saratzis, A. N., Reekers, J. A., et al. (2023) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2023.03.042 · Cited by 212
Lower extremity arterial disease in patients with diabetes: a contemporary narrative review
Nativel, M., Potier, L., Alexandre, L., Baillet‐Blanco, L., Ducasse, E., Velho, G., Marre, M., Roussel, R., Rigalleau, V., & Mohammedi, K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0781-1 · Cited by 207
Sex Differences in Peripheral Artery Disease
Pabón, M. A., Cheng, S. C., Altin, S. E., Sethi, S. S., Nelson, M. D., Moreau, K. L., Hamburg, N. M., & Hess, C. N. (2022) · Circulation Research · doi:10.1161/circresaha.121.320702 · Cited by 208
A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization
Hess, C. N., Norgren, L., Ansel, G. M., Capell, W. H., Fletcher, J., Fowkes, F. G. R., Gottsäter, A., Hitos, K., Jaff, M. R., Nordanstig, J., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.024469 · Cited by 168
Self-citation
Contemporary Medical Management of Peripheral Artery Disease
Bonaca, M. P., Hamburg, N. M., & Creager, M. A. (2021) · Circulation Research · doi:10.1161/circresaha.121.318258 · Cited by 170
Mortality and Paclitaxel-Coated Devices
Rocha‐Singh, K. J., Duval, S., Jaff, M. R., Schneider, P. A., Ansel, G. M., Lyden, S. P., Mullin, C. M., Ioannidis, J. P. A., Misra, S., Tzafriri, A. R., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044697 · Cited by 162
Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting
Franzone, A., McFadden, E. P., Leonardi, S., Piccolo, R., Vranckx, P., Serruys, P. W. J. C., Benit, E., Liebetrau, C., Janssens, L., Ferrario, M., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1038 · Cited by 149
Racial and Ethnic Disparities in Peripheral Artery Disease
Hackler, E. L., Hamburg, N. M., & White Solaru, K. T. (2021) · Circulation Research · doi:10.1161/circresaha.121.318243 · Cited by 141
Acute Limb Ischemia in Peripheral Artery Disease
Hess, C. N., Huang, Z., Patel, M. R., Baumgärtner, I., Berger, J. S., Blomster, J., Fowkes, F. J. I., Held, P., Jones, W. S., Katona, B. G., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.039773 · Cited by 144
Self-citation
Pharmacogenetics to guide cardiovascular drug therapy
Duarte, J. D., & Cavallari, L. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00549-w · Cited by 119
Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy
Aboyans, V., Bauersachs, R. M., Mazzolai, L., Brodmann, M., Rodríguez-Palomares, J. F., Debus, S., Collet, J., Drexel, H., Espinola–Klein, C., Lewis, B. S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab390 · Cited by 148
Vascular complications of diabetes: A narrative review
Lu, Y., Wang, W., Liu, J., Xie, M., Liu, Q., & Li, S. (2023) · Medicine · doi:10.1097/md.0000000000035285 · Cited by 171
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)
Capell, W. H., Bonaca, M. P., Nehler, M. R., Chen, E., Kittelson, J. M., Anand, S. S., Berkowitz, S. D., Debus, E. S., Fanelli, F., Haskell, L. P., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.01.011 · Cited by 135
Self-citation
Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease
Capodanno, D., Bhatt, D. L., Eikelboom, J. W., Fox, K. A. A., Geisler, T., Gibson, C. M., González‐Juanatey, J. R., James, S. K., Lópes, R. D., Mehran, R., et al. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0314-y · Cited by 123
Self-citation
Current Status and Principles for the Treatment and Prevention of Diabetic Foot Ulcers in the Cardiovascular Patient Population: A Scientific Statement From the American Heart Association
Gallagher, K. A., Mills, J. L., Armstrong, D. G., Conte, M. S., Kirsner, R. S., Minc, S. D., Plutzky, J., Southerland, K. W., & Tomic‐Canic, M. (2023) · Circulation · doi:10.1161/cir.0000000000001192 · Cited by 134
The Role of Clopidogrel in 2020: A Reappraisal
Patti, G., Micieli, G., Cimminiello, C., & Bolognese, L. (2020) · Cardiovascular Therapeutics · doi:10.1155/2020/8703627 · Cited by 129
Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs
Patti, G., Cavallari, I., Andreotti, F., Calabrò, P., Cirillo, P. L., Denas, G., Galli, M., Golia, E., Maddaloni, E., Marcucci, R., et al. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0080-2 · Cited by 122
Major Adverse Limb Events and 1-Year Outcomes After Peripheral Artery Revascularization
Hess, C. N., Rogers, R. K., Wang, T. Y., Fu, R., Gundrum, J. D., LaPointe, N. M. A., & Hiatt, W. R. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.041 · Cited by 116
Self-citation
Association of Blood Pressure Measurements With Peripheral Artery Disease Events
Itoga, N. K., Tawfik, D. S., Lee, C. K., Maruyama, S., Leeper, N. J., & Chang, T. I. (2018) · Circulation · doi:10.1161/circulationaha.118.033348 · Cited by 119
Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease
Gutierrez, J. A., Mulder, H. S., Jones, W. S., Rockhold, F. W., Baumgärtner, I., Berger, J. S., Blomster, J., Fowkes, F. G. R., Held, P., Katona, B. G., et al. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.5239 · Cited by 120
Self-citation
Interventions for lower extremity peripheral artery disease
Hiramoto, J. S., Teraa, M., de Borst, G. J., & Conte, M. S. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0005-0 · Cited by 109
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization
Hiatt, W. R., Bonaca, M. P., Patel, M. R., Nehler, M. R., Debus, E. S., Anand, S. S., Capell, W. H., Brackin, T., Jaeger, N., Hess, C. N., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.050465 · Cited by 113
Self-citation
Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease
Gurbel, P. A., Fox, K. A. A., Tantry, U. S., Cate, H. T., & Weitz, J. I. (2019) · Circulation · doi:10.1161/circulationaha.118.033580 · Cited by 105
Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease
Wang, C. C. L., Blomster, J., Heizer, G., Berger, J. S., Baumgärtner, I., Fowkes, F. G. R., Held, P., Katona, B. G., Norgren, L., Jones, W. S., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.078 · Cited by 110
Self-citation
Long-Term Outcomes and Associations With Major Adverse Limb Events After Peripheral Artery Revascularization
Hess, C. N., Wang, T. Y., Fu, J. W., Gundrum, J. D., LaPointe, N. M. A., Rogers, R. K., & Hiatt, W. R. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.050 · Cited by 99
Self-citation
Antiplatelet therapy in cardiovascular disease: Current status and future directions
Passacquale, G., Sharma, P., Perera, D., & Ferro, A. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15221 · Cited by 107
Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial
Schunkert, H., Boening, A., von Scheidt, M., Lanig, C., Gusmini, F., de Waha, A., Kuna, C., Fach, A., Grothusen, C., Oberhoffer, M. M., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz185 · Cited by 96
Review of aspirin and clopidogrel resistance in peripheral arterial disease
Guirgis, M., Thompson, P. L., & Jansen, S. J. (2017) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2017.07.065 · Cited by 91
Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery
Conflitti, P., Lyman, E. R., Sansom, M. S. P., Hildebrand, P. W., Gutiérrez‐de‐Terán, H., Carloni, P., Ansell, T. B., Yuan, S., Barth, P., Robinson, A. S., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01083-3 · Cited by 100
Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis
D’Alessandro, E., Becker, C., Bergmeier, W., Bode, C., Bourne, J. H., Brown, H. C., Buller, H. R., ten Cate‐Hoek, A. J., ten Cate, V., van Cauteren, Y. J. M., et al. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1708035 · Cited by 91
The coagulation system in atherothrombosis: Implications for new therapeutic strategies
Olie, R. H., van der Meijden, P. E. J., & Cate, H. T. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12080 · Cited by 88
Conformable microneedle pH sensors via the integration of two different siloxane polymers for mapping peripheral artery disease
Lee, W., Jeong, S., Lim, Y., Lee, H., Kang, J., Lee, H., Lee, I., Han, H., Kobayashi, S., Tanaka, M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi6290 · Cited by 83
Medical and lifestyle management of peripheral arterial disease
Parvar, S., Fitridge, R., Dawson, J. A., & Nicholls, S. J. (2018) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2018.07.027 · Cited by 81
Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease: A Report from the Asian Pacific Society of Atherosclerosis and Vascular Disease Asia-Pacific Peripheral Artery Disease Consensus Statement Project Committee
Abola, M. T. B., Golledge, J., Miyata, T., Rha, S., Yan, B. P., Dy, T. C., Ganzon, M. S. V., Handa, P. K., Harris, S., Jiang, Z., et al. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.53660 · Cited by 81
Novel Antiplatelet Therapies for Atherothrombotic Diseases
Majithia, A., & Bhatt, D. L. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310955 · Cited by 81
Platelet-Derived MRP-14 Induces Monocyte Activation in Patients With Symptomatic Peripheral Artery Disease
Dann, R. B., Hadi, T., Montenont, E., Boytard, L., Alebrahim, D., Feinstein, J., Allen, N., Simon, R., Barone, K., Uryu, K., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.072 · Cited by 74
Self-citation
Antithrombotic Therapy for Peripheral Artery Disease
Hussain, M. A., Al-Omran, M., Creager, M. A., Anand, S. S., Verma, S., & Bhatt, D. L. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.483 · Cited by 69
Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD
Arora, S., Shemisa, K., Vaduganathan, M., Qamar, A., Gupta, A., Garg, S. K., Kumbhani, D. J., Mayo, H., Khalili, H., Pandey, A., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.470 · Cited by 68
Intracranial Hemorrhage During Dual Antiplatelet Therapy
Ha, A. C. T., Bhatt, D. L., Rutka, J. T., Johnston, S. C., Mazer, C. D., & Verma, S. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.048 · Cited by 73
Women and Peripheral Arterial Disease: A Review of Sex Differences in Epidemiology, Clinical Manifestations, and Outcomes
Srivaratharajah, K., & Abramson, B. L. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.01.009 · Cited by 66
Safety and Effectiveness of Contemporary P2Y 12 Inhibitors in an East Asian Population With Acute Coronary Syndrome: A Nationwide Population‐Based Cohort Study
Yun, J. E., Kim, Y. J., Park, J. J., Kim, S., Park, K., Cho, M. S., Nam, G., & Park, D. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012078 · Cited by 64
Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications
Sterpetti, A. V. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00891-3 · Cited by 60
Ticagrelor – toward more efficient platelet inhibition and beyond
Kubisa, M. J., Jeżewski, M. P., Gąsecka, A., Siller-Matula, J. M., & Postula, M. A. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s152369 · Cited by 65
Antithrombotic therapy in diabetes: which, when, and for how long?
Ajjan, R., Kietsiriroje, N., Badimón, L., Vilahur, G., Gorog, D. A., Angiolillo, D. J., Russell, D., Rocca, B., & Storey, R. F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab128 · Cited by 69
Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients
Darmon, A., Sorbets, E., Ducrocq, G., Elbez, Y., Abtan, J., Popovic, B., Ohman, E. M., Röther, J., Wilson, P. W. F., Montalescot, G., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.04.046 · Cited by 81
Premature atherosclerotic peripheral artery disease: An underrecognized and undertreated disorder with a rising global prevalence
Mehta, A., Dhindsa, D. S., Hooda, A., Nayak, A., Massad, C., Rao, B., Makue, L. F., Rajani, R. R., Alabi, O., Quyyumi, A. A., et al. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.06.005 · Cited by 64
The OAC3-PAD Risk Score Predicts Major Bleeding Events one Year after Hospitalisation for Peripheral Artery Disease
Behrendt, C., Kreutzburg, T., Nordanstig, J., Twine, C. P., Marschall, U., Kakkos, S. K., Aboyans, V., & Peters, F. (2022) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2021.12.019 · Cited by 62
Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea
Ortega‐Paz, L., Brugaletta, S., Ariotti, S., Akkerhuis, K. M., Karagiannis, A., Windecker, S., Valgimigli, M., & On behalf of the HI-TECH investigators (2018) · Circulation · doi:10.1161/circulationaha.118.034489 · Cited by 57
Stroke in Patients With Peripheral Artery Disease
Kolls, B. J., Sapp, S. K., Rockhold, F. W., Jordan, J. D., Dombrowski, K. E., Fowkes, F. G. R., Mahaffey, K. W., Berger, J. S., Katona, B. G., Blomster, J., et al. (2019) · Stroke · doi:10.1161/strokeaha.118.023534 · Cited by 54
Self-citation
Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease
Hess, C. N., Cannon, C. P., Beckman, J. A., Goodney, P. P., Patel, M. R., Hiatt, W. R., Mues, K. E., Orroth, K. K., Shannon, E., & Bonaca, M. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.060 · Cited by 54
Self-citation
Patients with healed diabetic foot ulcer represent a cohort at highest risk for future fatal events
Mader, J. K., Haas, W., Aberer, F., Boulgaropoulos, B., Baumann, P. M., Pandis, M., Horvath, K., Aziz, F., Köhler, G., Pieber, T. R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46961-8 · Cited by 52
Lower extremity artery disease in patients with type 2 diabetes
Buso, G., Aboyans, V., & Mazzolai, L. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319880044 · Cited by 48
How I use laboratory monitoring of antiplatelet therapy
Michelson, A. D., & Bhatt, D. L. (2017) · Blood · doi:10.1182/blood-2017-03-742338 · Cited by 53
Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease
Haine, A., Kavanagh, S. T., Berger, J. S., Hess, C. N., Norgren, L., Fowkes, F. G. R., Katona, B. G., Mahaffey, K. W., Blomster, J., Patel, M. R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.057 · Cited by 51
Self-citation
Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice
Zanchin, T., Temperli, F., Karagiannis, A., Zanchin, C., Räsänen, M., Koskinas, K. C., Stortecky, S., Hunziker, L., Praz, F., Blöchlinger, S., et al. (2018) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.117.006132 · Cited by 49
Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD
Hess, C. N., Debus, E. S., Nehler, M. R., Anand, S. S., Patel, M. R., Szarek, M. J., Capell, W. H., Hsia, J., Beckman, J. A., Brodmann, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.055146 · Cited by 50
Self-citation
Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization
Baumgärtner, I., Norgren, L., Fowkes, F. G. R., Mulder, H. S., Patel, M. R., Berger, J. S., Jones, W. S., Rockhold, F. W., Katona, B. G., Mahaffey, K. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.046 · Cited by 46
Self-citation
Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease
Olivier, C. B., Mulder, H. S., Hiatt, W. R., Jones, W. S., Fowkes, F. G. R., Rockhold, F. W., Berger, J. S., Baumgärtner, I., Held, P., Katona, B. G., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.4171 · Cited by 46
Self-citation
Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease
Long, C. A., Mulder, H. S., Fowkes, F. G. R., Baumgärtner, I., Berger, J. S., Katona, B. G., Mahaffey, K. W., Norgren, L., Blomster, J., Rockhold, F. W., et al. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.119.006399 · Cited by 45
Self-citation
Antiplatelet agents for chronic kidney disease
Natale, P., Palmer, S. C., Saglimbene, V. M., Ruospo, M., Razavian, M., Craig, J. C., Jardine, M., Webster, A. C., & Strippoli, G. F. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008834.pub4 · Cited by 45
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease
Secemsky, E. A., Yeh, R. W., Kereiakes, D. J., Cutlip, D. E., Steg, P. G., Massaro, J. M., Apruzzese, P. K., & Mauri, L. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2017.02.013 · Cited by 42
Peripheral artery disease and outcomes in patients with acute myocardial infarction
Attar, R., Wester, A., Koul, S. M., Eggert, S., & Andell, P. (2019) · Open Heart · doi:10.1136/openhrt-2018-001004 · Cited by 43
Epidemiology and Burden of Peripheral Artery Disease in People With Type 2 Diabetes: A Systematic Literature Review
Verma, S., Leiter, L. A., Mangla, K. K., NIELSEN, N. F., Hansen, Y., & Bonaca, M. P. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01606-6 · Cited by 52
Assessment and management of peripheral arterial disease: what every cardiologist should know
Tran, B. G. (2021) · Heart · doi:10.1136/heartjnl-2019-316164 · Cited by 42
A systematic review of the efficacy of aspirin monotherapy versus other antiplatelet therapy regimens in peripheral arterial disease
Beiswenger, A. C., Jo, A., Harth, K. C., Kumins, N. H., Shishehbor, M. H., & Kashyap, V. S. (2018) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2018.02.047 · Cited by 40
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial
Berger, J. S., Abramson, B. L., Lópes, R. D., Heizer, G., Rockhold, F. W., Baumgärtner, I., Fowkes, F. G. R., Held, P., Katona, B. G., Norgren, L., et al. (2018) · Vascular Medicine · doi:10.1177/1358863x18775594 · Cited by 40
Self-citation
Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases
Savarese, G., Reiner, M. F., Uijl, A., D’Amario, D., Agewall, S., Atar, D., Baumgärtner, I., Borghi, C., Carlo, M. D., Drexel, H., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz036 · Cited by 40
Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial
Qamar, A., Morrow, D. A., Creager, M. A., Scirica, B. M., Olin, J. W., Beckman, J. A., Murphy, S. A., & Bonaca, M. P. (2020) · Vascular Medicine · doi:10.1177/1358863x19892690 · Cited by 40
Role of diabetes in stroke: Recent advances in pathophysiology and clinical management
Bradley, S., Spring, K. J., Beran, R. G., Chatzis, D., Killingsworth, M. C., & Bhaskar, S. M. M. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3495 · Cited by 42
Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry
Abtan, J., Bhatt, D. L., Elbez, Y., Sorbets, E., Eagle, K. A., Reid, C. M., Baumgärtner, I., Wu, D., Hanson, M. E., Hannachi, H., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22721 · Cited by 40
Characteristics of atherosclerosis in femoropopliteal artery and its clinical relevance
Poredoš, P., Cevc, M., & Blinc, A. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.09.012 · Cited by 42
Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease
Gulizia, M. M., Colivicchi, F., Abrignani, M. G., Ambrosetti, M., Aspromonte, N., Barile, G., Caporale, R., Casolo, G., Chiuini, E., Lenarda, A. D., et al. (2018) · European Heart Journal Supplements · doi:10.1093/eurheartj/suy019 · Cited by 38
Baseline modern medical management in the BEST-CLI trial
Menard, M. T., Jaff, M. R., Farber, A. M., Rosenfield, K., Conte, M. S., White, C. J., Beckman, J. A., Choudhry, N. K., Clavijo, L., Huber, T. S., et al. (2023) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2023.05.006 · Cited by 36
Antithrombotic Therapy for Peripheral Artery Disease in 2018
Hess, C. N., & Hiatt, W. R. (2018) · JAMA · doi:10.1001/jama.2018.5422 · Cited by 36
Self-citation
Multidisciplinary Care for Critical Limb Ischemia: Current Gaps and Opportunities for Improvement
Armstrong, E. J., Alam, S., Henao, S., Lee, A. C., DeRubertis, B. G., Montero-Baker, M. F., Mena, C. I., Cua, B., Palena, L. M., Kovach, R. C., et al. (2019) · Journal of Endovascular Therapy · doi:10.1177/1526602819826593 · Cited by 36
Antithrombotic treatment in peripheral artery disease
Olinic, D.-M., Tataru, D. A., Homorodean, C., Spînu, M., & Olinic, M. (2017) · VASA · doi:10.1024/0301-1526/a000676 · Cited by 36
Umbrella review and meta-analysis of antiplatelet therapy for peripheral artery disease
Ambler, G. K., Waldron, C.-A., Contractor, U. B., Hinchliffe, R. J., & Twine, C. P. (2020) · Journal of British Surgery · doi:10.1002/bjs.11384 · Cited by 35

Authors: Hiatt, W. R., Fowkes, F. G. R., Heizer, G., Berger, J. S., Baumgartner, I., Held, P., Katona, B. G., Mahaffey, K. W., Norgren, L., Jones, W. S., Blomster, J., Millegård, M., Reist, C., & Patel, M. R.
Affiliations: University of Bern (CH)
ORCID: Hiatt, William R.
Berger, Jeffrey S.
Mahaffey, Kenneth W.
Norgren, Lars
Jones, W. Schuyler
Patel, Manesh R.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2017-01-05
Volume: 376
Issue: 1
Pages: 32-40
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1611688
OpenAlex: W2556414715
Cited by: 636
References: 14
Citations by year: 2026: 26 · 2025: 42 · 2024: 57 · 2023: 59 · 2022: 60 · 2021: 85 · 2020: 75 · 2019: 80 · 2018: 87 · 2017: 60
FWCI: 63.57
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Discovery Research Portal (University of Dundee) (publishedVersion, other-oa)
Lund University Publications (Lund University) (submittedVersion)
Funders: Amgen
Bristol-Myers Squibb
Eli Lilly and Company
AstraZeneca
GlaxoSmithKline
Sanofi
Purdue University
Boston Scientific Corporation
Cook Medical
Purdue Pharma
MyoKardia
Mitsubishi Tanabe Pharma Corporation
St. Jude Medical
Abbott Vascular
Janssen Research and Development
Duke Clinical Research Institute
Daiichi Sankyo Europe
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords: ticagrelor, clopidogrel, peripheral arterial disease, antiplatelet therapy, major bleeding, acute limb ischemia, cardiovascular events, ankle-brachial index, critical limb ischemia, claudication, lower extremity revascularization, cardiovascular mortality, ischemic stroke, myocardial infarction, P2Y12 inhibitors, aspirin, atherosclerosis
MeSH terms: Clopidogrel, Ticagrelor, Adenosine, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Hemorrhage, Humans, Intermittent Claudication, Ischemia, Leg, Male, Middle Aged, Platelet Aggregation Inhibitors, Ticlopidine, Kaplan-Meier Estimate, Peripheral Arterial Disease, Purinergic P2Y Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks